FDMT4D Molecular Therapeutics, Inc.
$12.69+53% 1Y
$12.69
$7.1952 weeks$16.74
The financials
4D Molecular Therapeutics, Inc. by the numbers
4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $3.8M in Q2 2026 (quarter ended Jun 30, 2026), up 25107% from the same quarter a year earlier. That came with net loss of $73M. For the full year FY2025, revenue was $85M (+230195% year on year) and net income −$140M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.8M | $15K | +25107% |
| Operating income | −$77M | −$59M | n/a |
| Net income | −$73M | −$55M | n/a |
| Diluted EPS | −$1.04 | −$0.98 | n/a |